1 Introduction

1 Introduction

This resource has been developed to provide practical information and advice on adopting NICE diagnostics guidance on quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care in people without rectal bleeding who have unexplained symptoms but do not meet the criteria for referral on a 2-week wait suspected cancer pathway.

The guidance includes 3 quantitative faecal immunochemical tests: OC Sensor, HM‑JACKarc, and FOB Gold. NICE's adoption team worked with contributors who are evaluating or have recently implemented OC Sensor or HM‑JACKarc in NHS organisations to gather their learning and experiences. The NICE adoption team has not identified any current NHS users of FOB Gold.

The NICE adoption team has also discussed the implementation of this technology with colleagues from NHS England, the British Society of Gastroenterology, Cancer Research UK and Bowel Cancer UK.

The information presented in this resource is intended for the sole purpose of supporting the NHS in adopting, evaluating the impact of adopting, or further researching this technology. It is complementary to the guidance and was not considered by the diagnostic assessment committee when developing its recommendations.

The benefits of using quantitative faecal immunochemical tests as reported by the NHS staff involved in producing this resource include:

  • better triage of patients into secondary care

  • avoiding unnecessary colonoscopies

  • possible reduction in the number of colonoscopies done

  • improved patient pathway with shorter waiting times for specialist review

  • increased patient compliance with faecal occult blood testing compared with the guaiac test

  • earlier identification of colorectal cancer.


This page was last updated: 17 January 2018